Ph.D. Candidate, Interdisciplinary Oncology Program
Michael Hall is a PhD student in the interdisciplinary oncology program under the co-supervision of Dr. Kevin Bennewith and Dr. Ramon Klein Geltink. Michael’s research focuses on better preparing CD8 (cytotoxic) T cells for Chimeric antigen receptor T cell therapy to improve breast tumour killing. The end goal of Michael’s research is to transfer hypoxia-exposed, pyruvate supplemented human CAR-T cells into cancer patients for improved breast cancer regression.